Daiichi Sankyo Europe GmbH

vorige Seite Seite 1 von 4 nächste Seite

Large Real-World Data Confirm Safety and Effectiveness of LIXIANA® (edoxaban) in Routine Clinical Practice for Elderly AF Patients with Comorbidities

Daiichi Sankyo Europe GmbH (hereafter, "Daiichi Sankyo") today announced outcomes from one of the largest observational studies in mainly Caucasian atrial fibrillation (AF) patients being treated with …

OTE0001
18.12.2019 09:01
 

Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA® (edoxaban) in Patients with Atrial Fibrillation

Daiichi Sankyo Company, Limited, (hereafter, Daiichi Sankyo) today announced results from ENTRUST-AF PCI, the first large randomised study to evaluate the efficacy and safety of once-daily edoxaban (known …

OTE0001
04.09.2019 08:01
 

ETNA-AF Registry Data Provide Real-world Evidence of the Efficacy and Safety Profile of LIXIANA® (edoxaban) in Elderly NVAF Patients

Daiichi Sankyo Europe GmbH (hereafter, "Daiichi Sankyo") today announced one-year outcomes results from a study of 24,962 patients with NVAF treated with edoxaban (known by the brand name LIXIANA®), …

OTE0002
02.09.2019 14:01
 

Data from the Non-interventional EMIT-AF

VTE Study Shows Low Thromboembolic and Bleeding Event Rates in Unselected Elderly AF/VTE Patients on Oral, Once-daily LIXIANA® Undergoing Diagnostic or Therapeutic Procedures

OTE0008
19.03.2019 10:31
 

CLEAR Wisdom Demonstrated First-in-class, Oral, Once-daily, ACL Inhibitor Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP

Daiichi Sankyo Europe GMbH (hereafter, 'Daiichi Sankyo') and Esperion (NASDAQ: ESPR) today announced that the Phase 3 results from CLEAR Wisdom of first-in-class, oral, once-daily ATP citrate lyase (ACL) …

OTE0006
19.03.2019 09:59
 

Daiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral, Once-daily LIXIANA® (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter Ablation

* ELIMINATE-AF is the first set of data presented in 2019 from the Edoxaban Clinical Research Programme, which will deliver new evidence to support the use of edoxaban in clinical practice

OTE0001
18.03.2019 15:01
 

New Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-daily LIXIANA® (edoxaban)

* Hokusai-VTE CANCER study showed that oral edoxaban is non-inferior to subcutaneous injectable dalteparin, for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in …

OTE0001
06.08.2018 09:01
 

LIXIANA® (edoxaban) Shows Reduced Rate of a Variety of Types of Intracranial Haemorrhage Compared to Warfarin in New Sub-analysis Presented at the European Stroke Organisation Conference 2018

Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo), today announced new sub-analysis data from the ENGAGE AF-TIMI 48 trial, which demonstrates that patients with atrial fibrillation (AF) treated with …

OTE0001
18.05.2018 14:08
 
OTE0003
12.12.2017 13:55
 

New Sub-analysis Data Highlights the Benefit of LIXIANA® (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk Scoring

Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced new sub-analysis data, demonstrating that LIXIANA® (edoxaban) provides comparable efficacy and greater safety compared to warfarin, …

OTE0002
29.08.2017 14:03
 

CHMP Issues a Positive Opinion for Daiichi Sankyo's Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion

Daiichi Sankyo Europe GmbH (hereafter, "Daiichi Sankyo") today announced that the European Committee for Medicinal Products for Human Use (CHMP) has recommended approval of a label update for the company's …

OTE0001
17.07.2017 09:03
 

Daiichi Sankyo Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation

Daiichi Sankyo Europe GmbH (hereafter, "Daiichi Sankyo") today announced that the first patient has been enrolled into the ENVISAGE-TAVI AF study.

OTE0005
27.04.2017 15:04
 

Daiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily LIXIANA® (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation

Daiichi Sankyo Europe GmbH (hereafter, "Daiichi Sankyo") today announced that the first patient has been enrolled into the ELIMINATE-AF study.

OTE0010
30.03.2017 14:03
 
vorige Seite nächste Seite